<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02322021</url>
  </required_header>
  <id_info>
    <org_study_id>E2609-G000-202</org_study_id>
    <nct_id>NCT02322021</nct_id>
  </id_info>
  <brief_title>Dose-Finding Study To Evaluate the Safety and Tolerability of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease</brief_title>
  <official_title>A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Dose-Finding Study To Evaluate the Safety and Tolerability of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 study to evaluate safety and tolerability of daily dosing with elenbecestat
      (proposed international proprietary name [pINN]) (E2609) in Mild Cognitive Impairment
      (MCI)/Prodromal participants and in participants with Mild to Moderate Dementia due to
      Alzheimer's Disease (referred to as mild to moderate AD).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent adverse event (TEAEs) and serious adverse events (SAEs)</measure>
    <time_frame>From the time the participant signs the informed consent form until up to 3 months after the last dose of study drug or up to approximately 51 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in cerebrospinal fluid (CSF) Abeta(1-x) and Abeta(1-42) after 4 weeks and 18 months of treatment in MCI/Prodromal participants and mild to moderate AD participants</measure>
    <time_frame>At 4 weeks and 18 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean plasma concentration of elenbecestat, including the effect of intrinsic and extrinsic factors [including N-acetyltransferase 2 (NAT2) phenotype]</measure>
    <time_frame>Baseline; predose (trough) and 1 to 6 hours postdose at Week 3, Week 13, Week 27, and Week 53; and 4 to 8 hours postdose at Week 5 and Week 79 (or early discontinuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean CSF concentration of elenbecestat, including the effect of intrinsic and extrinsic factors [including N-acetyltransferase 2 (NAT2) phenotype]</measure>
    <time_frame>Baseline, Week 5, Week 79 (or early discontinuation)</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Dementia, Alzheimer Type</condition>
  <arm_group>
    <arm_group_label>MCI/Prodromal Cohort: Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A low dose of elenbecestat (E2609) will be assessed. After 6 or more months of treatment with a low dose of elenbecestat (E609), participants with at least 3 months of treatment remaining will be re-assigned to receive a high dose of elenbecestat (E2609) for the remainder of the double-blind treatment period. Eligible participants will receive a high dose of open-label elenbecestat (E2609) during the Open-Label Extension (OLE) Phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCI/Prodromal Cohort: Middle Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A middle dose of elenbecestat (E2609) will be assessed. After 6 or more months of treatment with a middle dose of elenbecestat (E2609), participants with at least 3 months of treatment remaining will be re-assigned to receive a high dose of elenbecestat (E2609) for the remainder of the double-blind treatment period. Eligible participants will receive a high dose of open-label elenbecestat (E2609) during the OLE Phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCI/Prodromal Cohort: High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A high dose of elenbecestat will be assessed during the double-blind treatment period and during the OLE Phase for participants meeting OLE eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCI/Prodromal Cohort: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During the double-blind portion of the study, two matching placebo tablets will be administered daily. During the OLE Phase, participants will receive the high dose as a single tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild to Moderate AD Cohort: Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A low dose of elenbecestat (E2609) will be assessed. After 6 or more months of treatment with a low dose of elenbecestat (E2609), participants with at least 3 months of treatment remaining will be re-assigned to receive a high dose of elenbecestat (E2609) for the remainder of the double-blind treatment period. Eligible participants will receive a high dose of open-label elenbecestat (E2609) during the OLE Phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild to Moderate AD cohort: Middle Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A middle dose of elenbecestat (E2609) will be assessed. After 6 or more months of treatment with a middle dose of elenbecestat (E2609), participants with at least 3 months of treatment remaining will be re-assigned to receive a high dose of elenbecestat (E2609) for the remainder of the double-blind treatment period. Eligible participants will receive a high dose of open-label elenbecestat (E2609) during the OLE Phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild to Moderate AD Cohort: High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A high dose of elenbecestat will be assessed during the double-blind treatment period and during the OLE Phase for participants meeting OLE eligibility criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild to Moderate AD Cohort: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During the double-blind portion of the study, two matching placebo tablets will be administered daily. During the OLE Phase, participants will receive the high dose as a single tablet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elenbecestat (E2609)</intervention_name>
    <description>In the double-blind portion of the study, each participant will receive two tablets, which when combined will make up the required dose of elenbecestat (E2609) or placebo, to be administered orally once per day (QD) with food. During the OLE Phase, participants will receive a single tablet of elenbecestat (E2609).</description>
    <arm_group_label>MCI/Prodromal Cohort: Low Dose</arm_group_label>
    <arm_group_label>MCI/Prodromal Cohort: Middle Dose</arm_group_label>
    <arm_group_label>MCI/Prodromal Cohort: High Dose</arm_group_label>
    <arm_group_label>Mild to Moderate AD Cohort: Low Dose</arm_group_label>
    <arm_group_label>Mild to Moderate AD cohort: Middle Dose</arm_group_label>
    <arm_group_label>Mild to Moderate AD Cohort: High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>In the double-blind portion of the study, each participant will receive two tablets, which when combined will make up the required dose of elenbecestat (E2609) or placebo, to be administered orally QD with food.</description>
    <arm_group_label>MCI/Prodromal Cohort: Placebo</arm_group_label>
    <arm_group_label>Mild to Moderate AD Cohort: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Participants must meet all of the following criteria to be included in the Core Study
        (Prerandomization and Randomization Phases):

          1. Meets the core clinical research criteria of the NIA-AA for MCI due to AD (which is
             consistent with Prodromal AD) or AD dementia and is 'staged' or classified as either
             MCI or mild to moderate dementia.

          2. Amyloid positive Positron Emission Tomography (PET) image based on centralized PET
             scan reading.

          3. Male or female, age 50 to 85 years, inclusive at time of consent.

          4. Must have an identified caregiver or informant who is willing and able to provide
             follow-up information on the participant throughout the course of the study.

          5. If receiving an Acetylcholinesterase Inhibitor (AChEI) or memantine, must have been on
             a stable dose for at least 12 weeks before the Baseline cognitive assessments, with no
             plans for dose adjustment in the foreseeable future. Treatment-naive participants can
             be entered into the study but there should be no plans to initiate treatment with
             AChEIs or memantine at the time of entry into the study.

          6. Must have been on stable doses of all other permitted chronically used concomitant
             medications (ie, not related to their cognitive decline) for at least 4 weeks before
             randomization.

        Participants must meet all of the following criteria to be included in the Open-Label
        Extension (OLE) Phase of the study:

          1. Participants who complete the 18-month treatment and the 12-week follow-up period
             (Visit 20) in the Core Study and whose Visit 20 falls within a 4-week window from the
             start of the OLE Phase (Visit 21). Permission must be obtained from the Medical
             Monitor if the Visit 21 is to occur more than 4 weeks from Visit 20.

          2. Participants must continue to have an identified caregiver or informant who is willing
             and able to provide follow-up information on the participant throughout the course of
             the OLE Phase.

        Exclusion criteria:

        Participants who meet any of the following criteria will be excluded from the Core Study:

          1. Any neurological condition that may be contributing to cognitive impairment above and
             beyond that caused by the participant's AD pathology, including any co-morbidities
             such as cerebrovascular disease, detected by medical history, neurological
             examination, or magnetic resonance imaging (MRI).

          2. History of transient ischemic attacks or stroke within 12 months of Screening.

          3. History of epilepsy.

          4. Evidence of depression on a rating scale at Screening or any psychiatric diagnosis or
             symptoms, (eg, hallucinations, major depression, etc.) that could confound the
             diagnosis or could interfere with study assessments or procedures. This includes
             suicidal ideation or suicidal behavior within 6 months prior to Screening, or
             hospitalization or treatment for suicidal behavior in the past 5 years.

          5. Abnormally low serum vitamin B12.

          6. Thyroid stimulating hormone above the normal range. This applies to all participants
             regardless of whether or not they are taking thyroid supplements.

          7. Participants with liver disease (hepatic impairment), at Screening or Baseline.
             Participants with Gilbert's syndrome need not be excluded.

          8. Not able to have a MRI, PET scanning, or CSF collection by Lumbar Puncture (LP)
             (applicable to participants consenting to CSF sample collection).

          9. Severe visual or hearing impairment that would prevent the participant from performing
             psychometric tests accurately.

         10. History of immunodeficiency disorders.

         11. Participants with chronic viral hepatitis.

         12. History of Tuberculosis (TB). Participants with no history of TB will be tested for
             previous TB exposure and a positive test will be exclusionary.

         13. History of ophthalmic shingles or ocular Herpes Simplex Virus (HSV) infection.

         14. Any live vaccine in the 3 months or any active infection within the last 4 weeks
             before study drug administration (i.e. randomization).

         15. Any chronic inflammatory disease that is not adequately controlled or requires
             immunosuppressive or immunomodulatory therapy.

         16. T helper cell, cytotoxic T cell, or B cell absolute counts below normal.

         17. Immunoglobulin (Ig) IgG, IgA, or IgM levels below normal at Screening or Baseline,
             unless both the Investigator and the Medical Monitor agree that the finding is not
             clinically significant.

         18. Clinically significant deviation from normal in physical examination, vital signs, or
             clinical laboratory tests at Screening or Baseline.

         19. Exclusionary cardiac factors include: prolonged QT interval greater than 450
             milliseconds (msec) from electrocardiograms (ECGs); history of risk factors for
             torsade de pointes or the use of concomitant medications that prolong the QT/QTc
             interval; left bundle branch block; persistent low or high heart rate; persistent low
             or high blood pressure; history of cardiac arrhythmias; other clinically significant
             ECG abnormalities.

         20. Type 1 or Type 2 diabetes mellitus that is not well controlled.

         21. Malignant neoplasms within 5 years before Screening (except for basal or squamous cell
             carcinoma in situ of the skin, or localized prostate cancer that did not require
             systemic therapy; these do not exclude the participant).

         22. Medical conditions (eg, cardiac, respiratory, gastrointestinal, renal disease) that
             are not stably controlled, or which, in the opinion of the investigator(s), could
             affect the participant's safety or interfere with the study assessments.

         23. Hypopigmentation conditions (eg, albinism and vitiligo).

         24. Known or suspected history of drug or alcohol dependency or abuse within 2 years,
             current use of recreational drugs or a positive urine drug test.

         25. Planned surgery that requires general, spinal, or epidural anesthesia that would take
             place during the study.

         26. Participation in any other interventional clinical study related to cognitive
             impairment within 6 months before Screening unless it can be documented that the
             participant was in a placebo treatment arm.

         27. Currently enrolled in another clinical study or used any investigational drug or
             device within 60 days or 5 half-lives of the investigational medication (whichever is
             longer) proceeding informed consent.

         28. Hypersensitivity to the study drug or any of the excipients or to other Beta Secretase
             Cleaving Enzyme (BACE) inhibitors, or to the PET tracer, or components of its
             formulation.

         29. Females who are lactating or pregnant. Females of childbearing potential who do not
             agree to adhere to the protocol specified methods for avoiding pregnancy.

         30. Males who do not meet the protocol requirements for avoiding their partners becoming
             pregnant. Sperm donation is not permitted.

        Participants who meet any of the following criteria will be excluded from the OLE Phase of
        the study:

          1. Participants who discontinue study drug prematurely during the Core Study are not
             eligible to participate in the OLE Phase.

          2. Participants with any active infection within 4 weeks of Visit 21

          3. Participants with absolute lymphocyte count below the lower limit of normal (LLN)
             within 10 days of Visit 21

          4. Participants who develop the following conditions from the time of screening for the
             Core Study to the start of the OLE Phase:

               1. Hepatic impairment, with total bilirubin greater than 1.5 Ã— the upper limit of
                  normal (ULN) or International Normalized Ratio (INR) greater than 1.7.
                  Participants with Gilbert's syndrome need not be excluded on the basis of an
                  elevated bilirubin, provided that they have no other signs or symptoms suggestive
                  of hepatic impairment.

               2. Any contraindications to MRI scanning, including cardiac pacemaker/defibrillator
                  or ferromagnetic metal implants (eg, in skull; cardiac devices other than those
                  approved as safe for use in MRI scanners)

               3. Severe visual or hearing impairment that would prevent the participant from
                  performing psychometric tests accurately

               4. Immunoglobulin (Ig) deficiency or other immunodeficiency disorders

               5. Chronic viral hepatitis

               6. Tuberculosis

               7. Ophthalmic shingles

               8. Ocular herpes simplex virus (HSV) infection

               9. Any chronic inflammatory disease that is not adequately controlled or that
                  requires systemic or ocular immunosuppressive or immunomodulatory therapy.
                  Participants with:

                    -  Seasonal or perennial allergic rhinitis, asthma or chronic obstructive
                       pulmonary disease where the condition is considered to be stable and
                       adequately controlled by inhaled steroids need not be excluded

                    -  Hashimoto's thyroiditis but who are stable on thyroid replacement therapy
                       and not on systemic immunosuppressive therapy need not be excluded

                    -  Cutaneous manifestations of immunological disease that do not require
                       systemic immunosuppressive therapy or systemic immunomodulatory therapy need
                       not be excluded (topical steroid treatment is permitted)

              10. Malignant neoplasms (except for basal or squamous cell carcinoma in situ of the
                  skin, or localized prostate cancer that did not require systemic therapy; these
                  do not exclude the subject from OLE).

          5. Participants with prolonged QT interval corrected by the Fridericia correction formula
             (QTcF) at Visit 20 or Visit 21. Participants with a single 12-lead ECG QTcF &gt;450 msec
             should have 2 additional ECGs performed at least 1 minute apart and the mean QTcF from
             the triplicate ECGs should be calculated. Participants with a mean QTcF value &gt;450
             msec are not eligible to enter the OLE Phase.

          6. Participants with significant pathological findings on brain MRI including but not
             limited to: an area of superficial siderosis; evidence of cerebral vasogenic edema;
             evidence of cerebral contusion, encephalomalacia, aneurysms, vascular malformations,
             or infective lesions; evidence of multiple lacunar infarcts or stroke involving a
             major vascular territory, severe small vessel, or white matter disease; space
             occupying lesions; or brain tumors (however, lesions diagnosed as meningiomas or
             arachnoid cysts and less than 1 centimeter at their greatest diameter need not be
             exclusionary).

          7. Participants who have a &quot;yes&quot; answer to the Columbia Suicide Severity Rating Scale
             (C-SSRS) suicidal ideation questions 4 or 5 at Visit 20 or Visit 21 or any suicidal
             behavior during the study prior to the start of the OLE Phase.

          8. Females who are lactating or pregnant. Females of childbearing potential who do not
             agree to adhere to the protocol specified methods for avoiding pregnancy.

          9. Participants with medical conditions (eg, cardiac, respiratory, gastrointestinal,
             renal disease) that are not stably controlled, or which, in the opinion of the
             investigator(s), could affect the participant's safety or interfere with the study
             assessments.

         10. Any other clinically significant abnormal findings in vital signs, ECGs and laboratory
             tests that would, in the investigator's opinion, affect the particiapant's safety or
             interfere with study assessments during the OLE Phase
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CITrials</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ATP Clinical Research</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Behavioral Research Specialists</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nervepro Research</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JEM Research LLC</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Research and Clinical Trials LLC</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders Center of Boca Raton Inc</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradenton Research Center Inc</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berma Research Group</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galiz Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alzheimers Research and Treatment Center</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCM Clinical Research Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Jewish Health Systems</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurostudies Inc</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stedman Clinical Trials</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurostudies Inc</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Georgia Geriatrics</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borgess Research Institute</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precise Research Centers</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The NeuroCognitive Institute</name>
      <address>
        <city>Mount Arlington</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognitive Research Center of New Jersey</name>
      <address>
        <city>Springfield</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ANI Neurology, PLLC dba Alzheimer's Memory Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Clinical Research Partners LLC</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Diagnostics, Inc.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Neurologic Associates</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Mood and Memory Research Institute</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Neurology</name>
      <address>
        <city>Port Royal</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Consultants of Dallas, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas Incorporated</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2014</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E2609</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Mild to Moderate Dementia</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Prodromal Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

